Jordan N Noble1, Anjali Mishra2,3,4,5. 1. College of Medicine, The Ohio State University, Columbus, OH, 43210, USA. 2. College of Medicine, The Ohio State University, Columbus, OH, 43210, USA. Anjali.Mishra@jefferson.edu. 3. Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA. Anjali.Mishra@jefferson.edu. 4. Division of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. Anjali.Mishra@jefferson.edu. 5. Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Philadephia, PA, 19107, USA. Anjali.Mishra@jefferson.edu.
Abstract
PURPOSE OF REVIEW: Animal models have played an indispensable role in interpreting cancer gene functions, pathogenesis of disease, and in the development of innovative therapeutic approaches targeting aberrant biological pathways in human cancers. RECENT FINDINGS: These models have guided the therapeutic targeting of cancer-causing mutations and paved the way for assessing anti-cancer drug responses and the preclinical development of immunotherapies. The mammalian models of cancer utilize genetically edited or transplanted mice that develop fairly accurate disease histopathology. The mouse model also allows us to study the effect of tumor microenvironment in the development of lymphoma. The emergence of patient-derived xenografts provides a better opportunity for recapitulating primary lymphoma characteristics and researching personalized drug therapy. In conclusion, the refinement and advancement of available mouse models in lymphoma significantly minimize the therapeutic translational failures in patients.
PURPOSE OF REVIEW: Animal models have played an indispensable role in interpreting cancer gene functions, pathogenesis of disease, and in the development of innovative therapeutic approaches targeting aberrant biological pathways in humancancers. RECENT FINDINGS: These models have guided the therapeutic targeting of cancer-causing mutations and paved the way for assessing anti-cancer drug responses and the preclinical development of immunotherapies. The mammalian models of cancer utilize genetically edited or transplanted mice that develop fairly accurate disease histopathology. The mouse model also allows us to study the effect of tumor microenvironment in the development of lymphoma. The emergence of patient-derived xenografts provides a better opportunity for recapitulating primary lymphoma characteristics and researching personalized drug therapy. In conclusion, the refinement and advancement of available mouse models in lymphoma significantly minimize the therapeutic translational failures in patients.
Authors: Leo Zhang; Krystle Nomie; Hui Zhang; Taylor Bell; Lan Pham; Sabah Kadri; Jeremy Segal; Shaoying Li; Shouhao Zhou; David Santos; Shawana Richard; Shruti Sharma; Wendy Chen; Onyekachukwu Oriabure; Yang Liu; Shengjian Huang; Hui Guo; Zhihong Chen; Wenjing Tao; Carrie Li; Jack Wang; Bingliang Fang; Jacqueline Wang; Lei Li; Maria Badillo; Makhdum Ahmed; Selvi Thirumurthi; Steven Y Huang; Yiping Shao; Laura Lam; Qing Yi; Y Lynn Wang; Michael Wang Journal: Clin Cancer Res Date: 2017-03-27 Impact factor: 12.531
Authors: K Shimada; S Shimada; K Sugimoto; M Nakatochi; M Suguro; A Hirakawa; T D Hocking; I Takeuchi; T Tokunaga; Y Takagi; A Sakamoto; T Aoki; T Naoe; S Nakamura; F Hayakawa; M Seto; A Tomita; H Kiyoi Journal: Leukemia Date: 2016-03-22 Impact factor: 11.528
Authors: Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245
Authors: Brandon J Aubrey; Gemma L Kelly; Andrew J Kueh; Margs S Brennan; Liam O'Connor; Liz Milla; Stephen Wilcox; Lin Tai; Andreas Strasser; Marco J Herold Journal: Cell Rep Date: 2015-02-26 Impact factor: 9.423
Authors: K Pinz; H Liu; M Golightly; A Jares; F Lan; G W Zieve; N Hagag; M Schuster; A E Firor; X Jiang; Y Ma Journal: Leukemia Date: 2015-11-03 Impact factor: 11.528
Authors: Joydeep Bhadury; Lisa M Nilsson; Somsundar Veppil Muralidharan; Lydia C Green; Zhoulei Li; Emily M Gesner; Henrik C Hansen; Ulrich B Keller; Kevin G McLure; Jonas A Nilsson Journal: Proc Natl Acad Sci U S A Date: 2014-06-16 Impact factor: 11.205